Results 11 to 20 of about 2,105,900 (288)

Pharmacokinetics of Monoclonal Antibodies

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2017
Monoclonal antibodies (mAbs) have developed in the last two decades into the backbone of pharmacotherapeutic interventions in a variety of indications, with currently more than 40 mAbs approved by the US Food and Drug Administration, and several dozens ...
J. Ryman, B. Meibohm
semanticscholar   +4 more sources

MONOCLONAL ANTIBODIES

open access: yesHematology, Transfusion and Cell Therapy
Obinutuzumab, an anti CD-20 monoclonal antibody, can be used in combination with venetoclax, ibrutinib or acalabrutinib in CLL patients with newly diagnosed or relaps patient's treatment indications. Another anti CD-20 monoclonal antibody, rituximab, has
Zekeriya Aksöz
doaj   +2 more sources

Human monoclonal antibodies and monoclonal antibody multispecificity [PDF]

open access: yesBritish Journal of Cancer, 1987
The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and therefore are of limited value as blood borne agents.
AM Campbell, P Whitford, RE Leake
openaire   +2 more sources

Monoclonal Antibodies in Cancer Therapy

open access: yesAntibodies, 2020
Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action.
D. Zahavi, L. Weiner
semanticscholar   +1 more source

Monoclonal Antibodies as Neurological Therapeutics

open access: yesPharmaceuticals, 2021
Over the last 30 years the role of monoclonal antibodies in therapeutics has increased enormously, revolutionizing treatment in most medical specialties, including neurology.
Panagiotis Gklinos   +4 more
doaj   +1 more source

Broad neutralization of SARS-related viruses by human monoclonal antibodies

open access: yesScience, 2020
Seeking broad protection As scientists develop therapeutic antibodies and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the risk of emergent coronaviruses makes it important to also identify broadly protective antibodies.
Anna Z. Wec   +36 more
semanticscholar   +1 more source

Monoclonal Antibodies for Prevention and Treatment of COVID-19.

open access: yesJournal of the American Medical Association (JAMA), 2020
The coronavirus disease 2019 (COVID-19) pandemic has created a worldwide crisis and inspired an urgent search for prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Attention has focused on the development
M. Marovich, J. Mascola, M. Cohen
semanticscholar   +1 more source

Delineating Molecular Mechanisms of Squamous Tissue Homeostasis and Neoplasia: Focus on p63

open access: yesJournal of Skin Cancer, 2013
Mouse models have informed us that p63 is critical for normal epidermal development and homeostasis. The p53/p63/p73 family is expressed as multiple protein isoforms due to a combination of alternative promoter usage and C-terminal alternative splicing ...
Kathryn E. King   +3 more
doaj   +1 more source

Hybridoma technology; advancements, clinical significance, and future aspects

open access: yesJournal of Genetic Engineering and Biotechnology, 2021
Background Hybridoma technology is one of the most common methods used to produce monoclonal antibodies. In this process, antibody-producing B lymphocytes are isolated from mice after immunizing the mice with specific antigen and are fused with immortal ...
Sanchita Mitra, Pushpa Chaudhary Tomar
doaj   +1 more source

ON THE NOTION OF SYNERGY OF MONOCLONAL ANTIBODIES AS DRUGS [PDF]

open access: yesBiotechnologia Acta, 2013
History of developing synergy between monoclonal antibodies, anti-tumor activity of monoclonal antibodies against tyrosine-kinases receptors EGFR/ErbB-1 and HER2/ErbB-2 as well as growth factor VEGF in various combinations are considered in the article ...
Michael Sela
doaj   +1 more source

Home - About - Disclaimer - Privacy